Fewer eye injections for wet AMD? new trial tests quarterly faricimab
NCT ID NCT06742307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether faricimab (Vabysmo) injections given every 12-16 weeks can maintain stability in people with wet age-related macular degeneration (AMD) after an initial series of loading doses. The trial will enroll 40 adults over 50 with active wet AMD. The main goal is to see if vision and eye health stay stable for a year without needing more frequent shots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Faricimab (Vabysmo) injection
- What this could lead to
- If successful, this could show that wet age-related macular degeneration can be managed with fewer injections per year, reducing treatment burden for patients.
- What could go wrong
- This is a small, early-phase study with only 40 participants. The quarterly schedule may not prevent disease recurrence in all patients, and results may not apply to everyone with wet AMD.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION CHOROIDAL NEOVASCULARIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Ophthalmology, United Chrisitian Hospital
RECRUITINGHong Kong, Hong Kong